Adverse events were mild and balanced across treatment and placebo study arms. No serious adverse events occurred.
You Might Also Like
Explore This IssueFebruary 2017
Also By This Author
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
Acknowledgment: Thanks to Lara C. Pullen, PhD, a medical writer based in the Chicago area, for her assistance in writing the Efficacy & Safety of Guselkumab section of this column.
- Deodhar AA, Gottlieb AB, Boehncke WH, et al. Efficacy and safety results of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: A phase 2a, randomized, double-blind, placebo-controlled study [abstract]. Arthritis Rheumatol. 2016;68(suppl 10).
- Stendahl M. Fast-growing Burlington biotech Flexion files for approval of lead drug. Boston Business Journal. 2016 Dec 12.